Linezolid Accord

Linezolid, the active ingredient in Linezolid Accord, is an oxazolidinone presented as an oral dosage form for oral use. It treats infections caused by resistant Gram‑positive bacteria, including MRSA and VRE, and is used in pneumonia and skin infections.

GNH USA supplies Linezolid Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory documentation for global distribution. Customers benefit from reliable logistics, batch traceability, and responsive technical support.

Linezolid is an oxazolidinone antibacterial indicated for several serious Gram‑positive infections. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: effective treatment of skin, bloodstream and pulmonary infections caused by MRSA. - Vancomycin‑resistant Enterococcus (VRE) infections: provides an alternative therapy for VRE bacteremia and intra‑abdominal infections. - Community‑acquired bacterial pneumonia: used to treat pneumonia caused by susceptible Streptococcus pneumoniae and other pathogens. - Skin and soft tissue infections: resolves infections of the skin, subcutaneous tissue and wound infections caused by resistant Gram‑positive organisms.

Linezolid may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools that may be self‑limiting. - Headache: transient cranial discomfort. - Metallic taste: altered taste perception.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count. - Peripheral neuropathy: nerve pain or sensory changes. - Serotonin syndrome: risk when combined with serotonergic drugs. - Severe allergic reaction: anaphylaxis or angioedema.

When prescribing Linezolid, clinicians should observe several safety considerations. - Monitor blood counts: regular CBC to detect thrombocytopenia or anemia. - Assess renal function: adjust therapy in severe renal impairment. - Avoid serotonergic agents: risk of serotonin syndrome with SSRIs, SNRIs, MAO inhibitors. - Use cautiously in patients with a history of myelosuppression: increased risk of hematologic toxicity. - Review hepatic status: consider dose modification in significant liver disease. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Linezolid interacts with several drug classes; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - MAO inhibitors: can precipitate hypertensive crisis. - Serotonergic antidepressants (SSRIs, SNRIs, tricyclics): increase risk of serotonin syndrome. - Rifampin: induces metabolism, reducing linezolid exposure.

Moderate Interactions (Monitor Closely): - NSAIDs: may enhance bleeding risk when thrombocytopenia occurs. - Antacids containing aluminum or magnesium: may decrease absorption if taken simultaneously. - Warfarin: potential for altered INR, requiring coagulation monitoring.